{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T18:22:54Z","timestamp":1792174974140,"version":"4.4.0"},"reference-count":10,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2022,2,7]],"date-time":"2022-02-07T00:00:00Z","timestamp":1644192000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,2,7]],"date-time":"2022-02-07T00:00:00Z","timestamp":1644192000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Rev Nephrol"],"published-print":{"date-parts":[[2022,4]]},"DOI":"10.1038\/s41581-022-00544-5","type":"journal-article","created":{"date-parts":[[2022,2,7]],"date-time":"2022-02-07T06:15:53Z","timestamp":1644214553000},"page":"205-206","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":21,"title":["Belzutifan: a novel therapy for von Hippel\u2013Lindau disease"],"prefix":"10.1038","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6226-5667","authenticated-orcid":false,"given":"Jingcheng","family":"Zhou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7195-677X","authenticated-orcid":false,"given":"Kan","family":"Gong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,2,7]]},"reference":[{"key":"544_CR1","doi-asserted-by":"publisher","first-page":"706","DOI":"10.1093\/annonc\/mdz056","volume":"30","author":"B Escudier","year":"2019","unstructured":"Escudier, B. et al. Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann. Oncol. 30, 706\u2013720 (2019).","journal-title":"Ann. Oncol."},{"key":"544_CR2","doi-asserted-by":"publisher","first-page":"2036","DOI":"10.1056\/NEJMoa2103425","volume":"385","author":"E Jonasch","year":"2021","unstructured":"Jonasch, E. et al. Belzutifan for renal cell carcinoma in von Hippel\u2013Lindau disease. N. Engl. J. Med. 385, 2036\u20132046 (2021).","journal-title":"N. Engl. J. Med."},{"key":"544_CR3","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1038\/nrc885","volume":"2","author":"WG Kaelin Jr.","year":"2002","unstructured":"Kaelin, W. G. Jr. Molecular basis of the VHL hereditary cancer syndrome. Nat. Rev. Cancer 2, 673\u2013682 (2002).","journal-title":"Nat. Rev. Cancer"},{"key":"544_CR4","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1038\/ng0594-85","volume":"7","author":"JR Gnarra","year":"1994","unstructured":"Gnarra, J. R. et al. Mutations of the VHL tumour suppressor gene in renal carcinoma. Nat. Genet. 7, 85\u201390 (1994).","journal-title":"Nat. Genet."},{"key":"544_CR5","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1126\/science.284.5413.455","volume":"284","author":"CE Stebbins","year":"1999","unstructured":"Stebbins, C. E., Kaelin, W. G. Jr & Pavletich, N. P. Structure of the VHL\u2013ElonginC\u2013ElonginB complex: implications for VHL tumor suppressor function. Science 284, 455\u2013461 (1999).","journal-title":"Science"},{"key":"544_CR6","doi-asserted-by":"publisher","first-page":"E83","DOI":"10.1371\/journal.pbio.0000083","volume":"1","author":"K Kondo","year":"2003","unstructured":"Kondo, K., Kim, W. Y., Lechpammer, M. & Kaelin, W. G. Jr. Inhibition of HIF2\u03b1 is sufficient to suppress pVHL-defective tumor growth. PLoS Biol. 1, E83 (2003).","journal-title":"PLoS Biol."},{"key":"544_CR7","doi-asserted-by":"publisher","first-page":"2010","DOI":"10.1016\/S0022-5347(01)66674-6","volume":"154","author":"MM Walther","year":"1995","unstructured":"Walther, M. M., Lubensky, I. A., Venzon, D., Zbar, B. & Linehan, W. M. Prevalence of microscopic lesions in grossly normal renal parenchyma from patients with von Hippel-Lindau disease, sporadic renal cell carcinoma and no renal disease: clinical implications. J. Urol. 154, 2010\u20132014, discussion 2014\u20132015 (1995).","journal-title":"J. Urol."},{"key":"544_CR8","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1038\/nature19796","volume":"539","author":"W Chen","year":"2016","unstructured":"Chen, W. et al. Targeting renal cell carcinoma with a HIF-2 antagonist. Nature 539, 112\u2013117 (2016).","journal-title":"Nature"},{"key":"544_CR9","doi-asserted-by":"publisher","first-page":"802","DOI":"10.1038\/s41591-021-01324-7","volume":"27","author":"TK Choueiri","year":"2021","unstructured":"Choueiri, T. K. et al. Inhibition of hypoxia-inducible factor-2\u03b1 in renal cell carcinoma with belzutifan: a phase 1 trial and biomarker analysis. Nat. Med. 27, 802\u2013805 (2021).","journal-title":"Nat. Med."},{"key":"544_CR10","doi-asserted-by":"publisher","first-page":"2169","DOI":"10.1093\/hmg\/ddt069","volume":"22","author":"I Comino-M\u00e9ndez","year":"2013","unstructured":"Comino-M\u00e9ndez, I. et al. Tumoral EPAS1 (HIF2A) mutations explain sporadic pheochromocytoma and paraganglioma in the absence of erythrocytosis. Hum. Mol. Genet. 22, 2169\u20132176 (2013).","journal-title":"Hum. Mol. Genet."}],"container-title":["Nature Reviews Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41581-022-00544-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41581-022-00544-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41581-022-00544-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,23]],"date-time":"2022-03-23T10:43:40Z","timestamp":1648032220000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41581-022-00544-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2,7]]},"references-count":10,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2022,4]]}},"alternative-id":["544"],"URL":"https:\/\/doi.org\/10.1038\/s41581-022-00544-5","relation":{},"ISSN":["1759-5061","1759-507X"],"issn-type":[{"value":"1759-5061","type":"print"},{"value":"1759-507X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,2,7]]},"assertion":[{"value":"7 February 2022","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}